Article

RLE with pseudoaccommodative IOL shows promise

A new accommodating lens seems to be a safe option for properly selected patients, in whom excellent refractive results can be achieved.

Key Points

Dr. Shah presented data from a consecutive case series of 78 eyes that underwent clear lens extraction. The mean patient age was 51 years (range, 43 to 60 years). Thirty eyes were myopic (mean refraction, –12.0 D), and the remainder were hyperopic (mean refraction, +6.5 D), according to Dr. Shah. He is a consultant ophthalmic surgeon at the Birmingham and Midland Eye Centre, Birmingham, and the Midland Eye Institute, Solihull, U.K.

The IOL is a square-edged acrylic lens that can be injected through a 2.8-mm incision. Dr. Shah described the insertion procedure as very easy to perform, with no preoperative or postoperative care requirements.

"The best-corrected visual acuity (BCVA) was about 0 LogMAR. No patients lost a substantial amount of BCVA. One patient lost one line of vision (from 20/15 to 20/20). A large percentage of patients gained BCVA."

Quality of vision

This IOL is a pseudoaccommodative lens. When accommodation was measured with a push-pull technique, Dr. Shah said, "the mean subjective accommodative amplitude was about 2.4 ± 1.0 D 6 months after implantation. The lowest accommodative amplitude was 1.5 D, and the highest was 4.4 D. In another group of patients who underwent cataract extraction, some patients had up to 6.5 D of subjective accommodation."

With this type of IOL, Dr. Shah said, it is difficult to determine exactly how it works. "Objective tests of these lenses with automated refractors show lower values on the same patient than the subjective tests, yet the patients are very happy. So something that we are not measuring well must be happening.

"We achieved extremely good UCVA results with this lens that are comparable with most monofocal IOLs. The results of this study are probably better than most of the studies that have been published," Dr. Shah said. "Patient satisfaction is very high with this IOL. As with most of these types of lenses, most patients achieved very good intermediate vision, and a good percentage had good near vision. At this time, this is my standard lens for clear lens extractions."

The patients who received the IOL 2 years ago are being evaluated to determine the stability of the visual acuity over time, he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.